New lesions after MDT in PB and MB leprosy: A report of 28 cases

Indian Journal of Leprosy

Volumn 80, Issue 3, 2008, Pages 247-255

  Kar, H K ^b   Sharma, P ^a  

^a DR RAM MANOHAR LOHIA HOSPITAL   (India)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; LEPROSTATIC AGENT; LOXACIN; MINOCYCLINE; PREDNISOLONE; RIFAMPICIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; INFLAMMATION; MALE; MULTIBACILLARY LEPROSY; MYCOBACTERIUM LEPRAE; NERVE LESION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PAUCIBACILLARY LEPROSY; RELAPSE; SENSORY NERVE; SINGLE DRUG DOSE; SKIN DEFECT; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG COMBINATION; LEPROSY; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE;

ADOLESCENT; ADULT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEPROSY; MALE; MIDDLE AGED; RECURRENCE;

EID: 65649151338     PISSN: 02549395     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Girdhar BK, Girdhar A and Kumar A (2000). Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev. 71: 144-153.
2. Lewis FL, Conologue T and Harrop E (2008). Leprosy (Barrett TL,WellsMJ, LibowLF et al, Eds), http://www.emedicine.com/derm/ topic 223.htm.
3. Sharma P, Mukherjee R, Talwar GP et al (2005). Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years. Lepr Rev. 76: 127-143.
4. World Health Organization (2006). Global strategy for further reducing leprosy burden and sustaining leprosy control activities (2006-2010): operational guidelines. WHO, Geneva,WHO/SEA/GLP/2006.2,pp28.